Verrica Pharmaceuticals Company Insiders

VRCA Stock  USD 0.52  0.04  6.77%   
Verrica Pharmaceuticals' insiders are aggressively selling. The analysis of insiders' sentiment of trading Verrica Pharmaceuticals stock suggests that vertually all insiders are panicking at this time. Verrica Pharmaceuticals employs about 71 people. The company is managed by 10 executives with a total tenure of roughly 15 years, averaging almost 1.0 years of service per executive, having 7.1 employees per reported executive.
Ted White  CEO
President CEO, Director

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-03-17Christopher G HayesDisposed 4315 @ 0.65View
2024-07-22Ted WhiteDisposed 32469 @ 7.06View
Monitoring Verrica Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

Verrica Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.5989) % which means that it has lost $0.5989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.4658) %, meaning that it created substantial loss on money invested by shareholders. Verrica Pharmaceuticals' management efficiency ratios could be used to measure how well Verrica Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 8.15, whereas Return On Tangible Assets are forecasted to decline to (1.49). At present, Verrica Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 4 M, whereas Net Tangible Assets are forecasted to decline to about 39.3 M.
As of March 24, 2025, Common Stock Shares Outstanding is expected to decline to about 32.1 M. In addition to that, Net Loss is expected to decline to about (23.1 M)

Verrica Pharmaceuticals Workforce Comparison

Verrica Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,638. Verrica Pharmaceuticals claims roughly 71.0 in number of employees contributing just under 2% to equities under Health Care industry.

Verrica Pharmaceuticals Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verrica Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verrica Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Verrica Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Verrica Pharmaceuticals Notable Stakeholders

A Verrica Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Verrica Pharmaceuticals often face trade-offs trying to please all of them. Verrica Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Verrica Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ted WhitePresident CEO, DirectorProfile
John CPAInterim CFOProfile
Dave ZawitzCOO OfficerProfile
Eugene ScavolaExecutive OperationsProfile
Terence KohlerChief OfficerProfile
Dr MBAHead DevelopmentProfile
Christopher HayesSecretary, OfficerProfile
Joe BonaccorsoChief Commercial OfficerProfile
Gary MDChief OfficerProfile
David ZawitzChief OfficerProfile

About Verrica Pharmaceuticals Management Performance

The success or failure of an entity such as Verrica Pharmaceuticals often depends on how effective the management is. Verrica Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Verrica management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Verrica management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.41)(1.49)
Return On Capital Employed(2.62)(2.76)
Return On Assets(1.41)(1.49)
Return On Equity 7.77  8.15 
Please note, the presentation of Verrica Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verrica Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Verrica Pharmaceuticals' management manipulating its earnings.

Verrica Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Verrica Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Verrica Pharmaceuticals within its industry.

Verrica Pharmaceuticals Manpower Efficiency

Return on Verrica Pharmaceuticals Manpower

Revenue Per Employee106.6K
Revenue Per Executive756.6K
Net Loss Per Employee1.1M
Net Loss Per Executive7.7M
Working Capital Per Employee312.2K
Working Capital Per Executive2.2M

Complementary Tools for Verrica Stock analysis

When running Verrica Pharmaceuticals' price analysis, check to measure Verrica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verrica Pharmaceuticals is operating at the current time. Most of Verrica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Verrica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verrica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Verrica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing